51. Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis
- Author
-
Hector Chinoy, Ingrid E. Lundberg, Jiri Vencovsky, Pauline Ho, Kiran Putchakayala, Neil McHugh, Robert G. Cooper, Zoe E Betteridge, Katalin Dankó, and John B Winer
- Subjects
Adult ,Male ,0301 basic medicine ,autoantibodies ,Eukaryotic Initiation Factor-3 ,Blotting, Western ,Sensitivity and Specificity ,Severity of Illness Index ,Autoantigens ,Polymyositis ,Mass Spectrometry ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Reference Values ,Eukaryotic initiation factor ,medicine ,Humans ,Immunoprecipitation ,Lupus Erythematosus, Systemic ,Pharmacology (medical) ,Myositis ,Retrospective Studies ,Autoantibodies ,030203 arthritis & rheumatology ,biology ,business.industry ,Autoantibody ,Interstitial lung disease ,Middle Aged ,Clinical Science ,medicine.disease ,Blot ,Sjogren's Syndrome ,030104 developmental biology ,Case-Control Studies ,Rheumatoid arthritis ,Immunology ,Disease Progression ,biology.protein ,Female ,Rheumatic Fever ,Antibody ,business ,myositis ,Biomarkers ,Immunosuppressive Agents - Abstract
Objectives To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis. Methods Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen was identified through a combination of IPP and MALDI-TOF mass spectrometry, and confirmed using commercial antibodies and IPP-western blots. Additional samples from patients with DM (668), DM-overlap (80), PM-overlap (191), systemic sclerosis (150), systemic lupus erythematosus (200), Sjogren’s syndrome (40), rheumatoid arthritis (50) and healthy controls (150) were serotyped by IPP as disease or healthy controls. Results IPP revealed a novel pattern in three PM patients (0.44%) that was not found in disease-specific or healthy control sera. Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern for all positive patients. Mass spectrometry analysis of the protein complex identified the target autoantigen as eIF3, a cytoplasmic complex with a role in the initiation of translation. Findings were confirmed by IPP-Western blotting. The three anti-eIF3-positive patients had no history of malignancy or interstitial lung disease, and had a favourable response to treatment. Conclusion We report a novel autoantibody in 0.44% of PM patients directed against a cytoplasmic complex of proteins identified as eIF3. Although our findings need further confirmation, anti-eIF3 appears to correlate with a good prognosis and a favourable response to treatment.
- Published
- 2019